Johnson & Johnson: In advanced prostate cancer, its investigational pasritamig-based immunological combination therapy showed a 73% PSA remission rate.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.